If you find Creative Peptides is useful to satisfy your needs, please do not hesitate to contact us!
Terlipressin is a synthetic peptide agonist at vasopressin 1 receptors (AVPR1) and is clinically used to treat portal hypertension by decreasing portal pressure; it is an analog of vasopressin. Terlipressin is a vasopressin analog that exhibits both vasoconstrictive and antihypertensive activities in various models. Terlipressin induces gastroparesis in vivo, increasing slow wave frequency in stomach and intestines. Terlipressin may also improve renal function in subjects with hepatorenal syndrome. Terlipressin Acetate is an analogue of vasopressin used as a vasoactive for proteomics research. It has been found to be effective when norepinephrine is not.
Currently medical therapy is aimed at reducing splanchnic vasodilation to resolve the ineffective circulation and maintain good renal perfusion pressure. Terlipressin, a vasopressin analogue, has shown potential benefit in the treatment of HRS. It prolongs both survival time and has the ability to reverse HRS in the majority of patients. In this review we aim to focus on the pathogenesis of HRS and its treatment with terlipressin vs other drugs.
Magan, A. A., Khalil, A. A., & Ahmed, M. H. (2010). Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World journal of gastroenterology: WJG, 16(41), 5139.
Liver disease is usually accompanied with a decline in systemic vascular resistance (SVR). We decided to assess effects of the peri-operative terlipressin infusion on liver donor liver transplantation recipients with respect to haemodynamics and renal parameters.
Ibrahim, N., Hasanin, A., Allah, S. A., Sayed, E., Afifi, M., Yassen, K., ... & Khalil, M. (2015). The haemodynamic effects of the perioperative terlipressin infusion in living donor liver transplantation: A randomised controlled study. Indian journal of anaesthesia, 59(3), 156.
Terlipressin and somatostatin are the most preferable agents for the control of variceal bleeding in cirrhotic patients. The present study evaluated the hemodynamic effects of somatostatin, terlipressin and somatostatin plus terlipressin in cirrhotic patients with portal hypertension, as well as the effect of each regimen on renal sodium excretion.
Kalambokis, G., Economou, M., Paraskevi, K., Konstantinos, P., Pappas, C., Katsaraki, A., & Tsianos, E. V. (2005). Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis. Journal of gastroenterology and hepatology, 20(7), 1075-1081.